Nuvalent: Pioneering Targeted Cancer TherapiesNuvalent's dual ROS1/ALK inhibitor pipeline shows early clinical promise in TKI-resistant NSCLC, targeting a $10B+ market with a structure-based design that overcomes resistance mutations.Jun 95 min